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ABSTRACT
Screening of potential MRSA-positive patients at hospital admission is recommended in German and
international guidelines. This policy has been shown to be effective in reducing the frequency of
nosocomial MRSA transmissions in the event of an outbreak, but the inﬂuence of screening on reducing
hospital-acquired MRSA infections in a hospital setting where MRSA is endemic is not yet well-
documented. This study describes the effect of hospital-wide screening of deﬁned risk groups in a
700-bed acute care hospital during a period of 19 months. In a cohort study with a 19-month control
period, the frequencies of hospital-acquired MRSA infections were compared with and without
screening. In the control period, there were 119 MRSA-positive patients, of whom 48 had a hospital-
acquired MRSA infection. On the basis of this frequency, a predicted total of 73.2 hospital-acquired
MRSA infections was calculated for the screening period, but only 52% of the expected number
(38 hospital-acquired MRSA infections) were observed, i.e., 48% of the predicted number of hospital-
acquired MRSA infections were prevented by the screening programme. The screening programme was
performed with minimal effort and can therefore be recommended as an effective measure to help
prevent hospital-acquired MRSA infections.
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INTRODUCTION
Methods to reduce nosocomial transmission of
methicillin-resistant Staphylococcus aureus (MRSA)
include contact isolation precautions, measures to
decolonise MRSA carriers, staff education, screen-
ing for contacts, and screening of risk groups for
MRSA carriage at hospital admission [1,2]. The
major MRSA reservoir in the hospital setting is
the colonised or infected MRSA patient [1].
Microbiological screening at the point of hospital
admission is the only opportunity to detect MRSA
patients early enough to enable the implementa-
tion of timely contact isolation precautions that
will reduce the subsequent nosocomial spread of
this multiresistant organism. A major proportion
of all MRSA patients can be identiﬁed at the time
of hospital admission in a cost-effective manner
[3–5]. Thus, early screening of potential MRSA
carriers at hospital admission and implementa-
tion of contact isolation seems, in theory, to be a
reasonable method to prevent MRSA transmis-
sion in the hospital setting.
In The Netherlands, screening and preventive
contact isolation measures are enforced strictly.
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This ‘search and destroy’ strategy is able to curb
the frequency of nosocomial MRSA transmissions
in the case of a nosocomial MRSA outbreak [6].
However, the inﬂuence of this screening strategy
in preventing hospital-acquired MRSA infections
in a setting where MRSA is endemic has not yet
been well-documented. Some studies are only
descriptive [3,4,7–10] and are not well-designed
controlled trials, while others [11–15] introduced
or modiﬁed additional interventions to reduce
nosocomial MRSA transmission, so that the con-
tribution of screening is difﬁcult to determine. To
date, only two studies have attempted to investi-
gate systemically the inﬂuence of screening on
hospital-acquired MRSA infections, but their sig-
niﬁcance was limited because there was either no
comparison with a control group [16] or consid-
eration of the fact that screening produces an
increased frequency of MRSA patients because of
its active search strategies [5]. For this reason, the
total number of MRSA patients cannot be used as
a general denominator (relative frequency of
hospital-acquired MRSA infections) to compare
the frequency of hospital-acquired MRSA infec-
tions before and after intervention.
The aim of the present cohort study was to
investigate whether screening of deﬁned risk
groups for MRSA carriage, combined with pre-
ventive contact isolation at hospital admission
until microbiological surveillance showed no
evidence of MRSA, was able to prevent hospital-
acquired MRSA infections in a setting where
MRSA was endemic in the hospital.
MATERIALS AND METHODS
Setting
The Klinikum im Friedrichshain (located in the centre of
Berlin) is a 700-bed acute care university teaching hospital
with four intensive care units (ICUs) (total of 44 beds) and
23 general departments. In total, there are c.23 000 admis-
sions annually, with a mean hospital stay of 8.6 days ⁄
patient.
The ﬁrst patient with MRSA in the hospital was identiﬁed
in 1993. Between 1993 and 1998 there was a low endemic level
of MRSA, with an average incidence of 0.19 MRSA pa-
tients ⁄ 1000 admissions (1–4 MRSA patients ⁄ year), which
increased signiﬁcantly to 1.58 in 1999 (37 MRSA patients;
p < 0.001). The reason for this increase is unknown; no index
patient was identiﬁed and there were neither modiﬁcations in
microbiological diagnostic methods nor a change in recom-
mendations for antimicrobial drug usage. The trend of
increasing numbers of MRSA patients appeared in almost all
departments, with no limitation to high-risk areas such as
ICUs. No outbreaks or clusters with more than three
simultaneous patients in the same ward were identiﬁed.
Despite strict contact isolation precautions and decolonisation
of all MRSA patients since the appearance of the ﬁrst MRSA
patient in 1993, the incidence rate nevertheless increased to
3.34 ⁄ 1000 admissions in the year 2000 (78 MRSA patients;
p < 0.001) and 4.14 in the ﬁrst quarter of 2001. For that reason,
hospital-wide selective screening for MRSA carriers at hospital
admission was initiated on 1 April 2001.
Population
This study was conducted for two periods of 19 months
between 1 September 1999 and 31 March 2001 (control period)
and from 1 May 2001 to 30 November 2002 (screening period)
in all departments of the study hospital. The transition period
between the study periods (April 2001) was not taken into
account for analysis. During the study periods, all patients
admitted from whomMRSAwas detected, from any site at any
time during their hospital stay, were included in the analysis.
The study compared the frequency of hospital-acquired MRSA
infections before introduction of the screening programme
with the frequency after intervention. The study was approved
by the local Ethics Committee.
Screening programme
During the screening period, screening at hospital admission
was performed for potential MRSA patients. These were
deﬁned as follows: (i) patients with a known history of MRSA
colonisation or infection (all MRSA patients were recorded in a
computerised admission system and were recognised at
readmission); (ii) patients admitted directly from foreign
hospitals or hospitals where MRSA was endemic; and (iii)
patients with at least two of the following characteristics:
residing in a nursing home; requiring dialysis and with a skin
or soft tissue infection; receiving treatment involving any
invasive device; pressure sores; aged >65 years with acute
sialadenitis or diabetic gangrene. These criteria were based on
an analysis of the characteristics of MRSA patients before
introduction of the screening programme, and were in accord-
ance with recommendations in national and international
guidelines. Acute sialadenitis was deﬁned as a risk factor for
MRSA carriage at hospital admission because there was a
cluster of patients with MRSA sialadenitis in the otorhino-
laryngology department in the 3 months before introduction
of the screening programme. Swabs were taken immedi-
ately from nares, throat, skin or soft tissue lesions, the
surroundings of invasive devices and any other clinically
suspicious sites.
Contact isolation precautions
During both the control and the screening period, each MRSA
patient was placed in a single room, healthcare workers used
gloves, gowns and masks for patient care, and hand disinfec-
tion was mandatory after patient contact. There were only two
contact isolation rooms with an upstream changing cubicle
(one room at an ICU) in the hospital, but 82 of the 328 rooms
for patient care were single rooms, and 170 double rooms were
also available for preventive contact isolation precautions for
potential MRSA carriers and for patient care when MRSA
carriage was conﬁrmed. If there were two MRSA patients on
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the same ward simultaneously and insufﬁcient single rooms
were available, the patients were placed in a two-bed room
(cohort isolation). All MRSA patients and all potential MRSA
patients were washed routinely with undecylamidopropyl-
trimoniummethosulphate and phenoxyethanol-based antisep-
tic soap (Stellisept Scrub; Bode-Chemie, Hamburg, Germany).
Intranasal application of mupirocin (Turixin; GlaxoSmithK-
line, Munich, Germany) was performed only if MRSA was
conﬁrmed. If necessary because of clinical indications, sys-
temic antibiotics were administered in accordance with the
resistance proﬁle. Empirical therapy with vancomycin and
rifampicin was not used routinely for high-risk MRSA patients
with infection at hospital admission, but was administered
only if MRSA was conﬁrmed.
Twenty-four hours after decolonisation measures had been
performed for at least 5 days, three series of samples (nose and
throat, skin or soft tissue lesions, device localisations, wounds,
and all other sites where MRSA was detected initially) were
collected on three consecutive days. If all these samples were
MRSA-negative, contact isolation precautions were discontin-
ued. During the screening period, contact isolation precau-
tions, as detailed above, were performed for the potential
MRSA carriers upon hospital admission until the results of
microbiological tests showed no evidence of MRSA. If MRSA
was detected, contact isolation precautions and decolonisation
measures were continued.
Study deﬁnitions and data collecting
All MRSA patients were stratiﬁed initially into high-risk
MRSA patients if they exhibited the factors that qualiﬁed
them for screening (see above), or non-high-risk MRSA
patients when they did not belong to one of the risk groups.
The time at which MRSA occurred during their hospital stay
was not crucial for this classiﬁcation. Although there was no
MRSA screening during the control period, the terms ‘high-
risk MRSA patients’ and ‘non-high-risk MRSA patients’ were
used for all patients in both study period populations,
depending on whether or not they belonged to a risk group.
This stratiﬁcation was necessary for further statistical analysis.
The active search strategy for MRSA patients in the
screening period could have increased the total number of
high-risk MRSA patients in that period, and would have
reduced the proportion of hospital-acquired MRSA infections
if the number of all MRSA patients had been used as the
denominator (relative frequency), in turn giving an apparent
reduction in the relative frequency of hospital-acquired MRSA
infections unrelated to any effect of screening. To allow a
comparison of the two periods, hospital-acquired MRSA
infection rates were compared separately for high-risk MRSA
patients and non-high-risk MRSA patients by means of a
standardised infection ratio (see below).
In a second step, high-riskMRSA patients and non-high-risk
MRSA patients were classiﬁed as patients with hospital-
acquired MRSA infection (HA-MRSA-I), patients with com-
munity-acquired MRSA infection, and patients with MRSA
colonisation. HA-MRSA-I was recorded if the patient exhibited
clinical signs of infection ‡48 h after hospital admission, with
MRSA isolated as the causative pathogen. CDC criteria [17,18]
were applied to diagnose hospital-acquired infections. If the
patient developed more than one type of HA-MRSA-I simul-
taneously, the most invasive type of infection was included for
analysis. Community-acquired MRSA infection was recorded
if a patient with MRSA met CDC criteria <48 h following
admission. MRSA colonisation was recorded if no clinical
signs of infection appeared. There was no differentiation
between nosocomial and ambulant colonisations.
There was no active search strategy to detect patients with
MRSA colonisation during the control period. Such patients
were detected incidentally, or if specimens were collected
because of clinical indications, or in the context of cross-
infection investigations. During the screening period, data
were collected prospectively, while data from the control
period were collected retrospectively from medical records.
All data were collected by a single member of the study group.
For validation purposes, data for every tenth MRSA patient in
both study periods were collected independently by a second
investigator and compared with the results of the ﬁrst
investigator.
Statistics
Statistical analysis was performed with SPSS v.8.0 for Win-
dows (SPSS Inc., Chicago, IL, USA) and EpiInfo v.6.0 (CDC,
Atlanta, GA, USA). The two-tailed Fisher’s exact test was used
to compare two proportions, and the two-tailed t-test was used
to compare continuous variables. A p value of <0.05 was
considered to be statistically signiﬁcant.
If the screening strategy had no inﬂuence on the frequency
of HA-MRSA-I, the same percentages of HA-MRSA-I would
be expected in the screening period (separated for high-risk
and non-high-risk MRSA patients) as were observed in the
control period. Taking the percentages of HA-MRSA-I in the
control period, it was possible to calculate the expected
number of HA-MRSA-Is that would be observed in the
screening period if screening had no inﬂuence on these
infection rates. A ‘standardised infection ratio’ (SIR) was then
generated by dividing the actual number of hospital-acquired
infections observed during the screening period by the
expected number of HA-MRSA-Is. A value of 1.0 would mean
that screening has no inﬂuence on nosocomial infection rates; a
value of >1.0 would mean that HA-MRSA-Is were more
frequent in the screening period than in the control period;
and a value <1.0 would mean that there was a reduction in
HA-MRSA-Is. A 95% CI, not including a value of 1.0 (Poisson-
distribution was used), was taken as a measure of statistical
signiﬁcance.
Since there are no published controlled trials which
indicate the possible extent of a reduction in HA-MRSA-I, a
preliminary study was performed between 1 May 2001 and
31 December 2001 to estimate the required duration of a
screening period that would yield a signiﬁcant reduction in
HA-MRSA-I. The incidence rates of HA-MRSA-Is ⁄ 1000
admissions during the last 3 months of the control period
were used as the maximum value and compared with the
incidence rates of the preliminary study (an estimation of the
required duration using the SIR is not possible). The
preliminary study showed that HA-MRSA-I rates could
reduced by c.50% after intervention. Based on these results,
a ﬁgure of 36 HA-MRSA-Is was expected after 35 000
admissions, with an incidence rate of 1.03 (95% CI 0.72–
1.42) ⁄ 1000 admissions during the screening period. This
would demonstrate a signiﬁcant reduction n the HA-MRSA-
I incidence rates according to Fisher’s exact test. The length of
the control period was adjusted to the duration of the
screening period.
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Laboratory methods
Screening samples were obtained with Transystem swabs and
Amies transport medium (Copan Italy, Bovezzo, Italy). Sam-
ples were streaked on Colistin Nalidixic acid (CNA) blood
agar (Oxoid, Wesel, Germany) and ORSAB (oxacillin resist-
ance screening agar base; Oxoid), with samples from nose and
throat also being streaked on Columbia blood agar (Becton
Dickinson, Heidelberg, Germany). Following incubation at
37C for 24–48 h, plates were examined daily for colonies with
typical S. aureus morphology. These were screened with
Staphylase (Oxoid) and MRSA Screen latex agglutination
(Denka Seiken, Tokyo, Japan) tests, and were conﬁrmed as
S. aureus by a tube coagulase test. Antibiotic susceptibility
patterns were determined by agar dilution in accordance with
the German Institute for Standardisation (DIN) guidelines,
with mannitol-salt agar (oxacillin 2 mg ⁄L, NaCl 6 mg ⁄L) used
to test oxacillin resistance. For clinical samples, Columbia
blood and Chapman agar (bioMe´rieux, Nu¨rtingen, Germany)
were used for culturing S. aureus. Suspected colonies of
S. aureuswere tested as described above for screening samples.
MRSA isolates in the control period were conﬁrmed by
oxacillin Etest (MIC ‡ 4 mg ⁄L). Most MRSA isolates during
the control and screening periods were tested for the presence
of the mecA gene and typed by a REP-PCR-based method with
ERIC2 and ERIC1R primers as described previously [19]. The
nomenclature used for epidemic strains was that suggested by
Enright et al. [20].
RESULTS
During the control period, 36 118 inpatients,
including 119 MRSA patients, were observed,
compared with 36 962 inpatients, including 205
MRSA patients, during the screening period. The
incidence rate of MRSA patients increased from
3.3 ⁄ 1000 admissions during the control period to
5.6 ⁄ 1000 admissions during the screening period
(p < 0.001). Both populations were comparable in
terms of general patient characteristics (age, sex,
length of hospital stay, mortality, ASA score) and
the prevailing hospital conditions (patient–nurse
ratio, number of surgical or ventilation proce-
dures, use of invasive devices and antimicrobial
treatments with ﬂuoroquinolones and third-
generation cephalosporins). These characteristics
are shown in Table 1. The reduction in the
mortality rate of patients with MRSA colonisation
can be explained by the increasing number of
patients colonised only with MRSA because of the
active search strategy, thereby including patients
with less severe conditions in the screening
period.
Of the 119 MRSA patients in the control period,
51 met the criteria for high-risk MRSA patients,
compared with 114 of the 205 MRSA patients in
the screening period (Table 2). There were signi-
ﬁcantly more high-risk MRSA patients in the
screening period (p 0.03), which may be explained
either by the active search strategy for MRSA
carriers upon admission or by the increasing
incidence of MRSA in Germany. Of the 114 high-
risk MRSA patients in the screening period, 111
were detected by screening at hospital admission
(99 patients with MRSA colonisation, 11 patients
with community-acquired MRSA infection, and
one patient who was only colonised initially, but
developed an HA-MRSA-I during hospital stay).
Two of the remaining three high-risk patients
were sampled on admission, but were MRSA-
negative and developed an HA-MRSA-I during
their hospital stay. The remaining high-risk
patient was mistakenly not screened upon admis-
sion. During the control period, MRSA was
Table 1. Patient characteristics dur-
ing the control and screening periodsPatient characteristics
Control period
(19 months)
Screening period
(19 months)
All patients admitted to the study hospital
All admissions 36 118 36 962
Mean number of admissions ⁄month 1900.9 (SD 99.96) 1945.4 (SD 123.52)
Mean length of hospital stay (days)a 8.9 8.3
Mortality of patients (%) 2.7 2.5
Patient-to-nurse ratiob 4.0 4.3
Male patients (%) 44.6 46.0
Mean age (years) 44.7 (SD 26.7) 45.2 (SD 26.6)
Number of surgical procedures 18 809 19 900
Number of ventilation days 5196 6129
MRSA patients 119 205
Mean length of hospital stay (days) 32.7 (SD 23.8) 24.4 (SD 22.8)
Median days between admission and occurrence
of nosocomial MRSA infection
20.0 (range 4–86) 18.0 (range 5–71)
Male patients (%) 49.6 56.6
Mean age (years) 74.3 (SD 15.2) 71.5 (SD 15.7)
Mortality of patients with nosocomial MRSA infection (%) 22.9 31.6
Mortality of patients with MRSA colonisation (%) 28.2 14.4
aGenerated by dividing the number of total admissions by the cumulative length of hospital stay of all patients.
bCalculated by dividing the mean number of admissions ⁄month by the mean number of nursing staff employed.
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detected in high-risk MRSA patients after a
median 18 days (range 2–94 days).
During the screening period, 539 patients (1.5%
of 36 962 admissions; about one patient daily)
were screened, of whom 111 (20.6%) were MRSA-
positive. Only one MRSA-positive patient could
not be placed in a private room upon admission
because all the single and double-bed rooms were
already occupied. Nevertheless, screening sam-
ples were taken and healthcare workers wore
gowns, gloves and masks for patient care. The
patient was transferred to a private room on the
next day. The contact individuals were shown
to be MRSA-negative. Of the 111 MRSA-positive
patients, 33% were positive only in samples from
invasive devices, skin lesions or other clinically
suspicious sites, and no colonisation of the nose or
throat was detected. Fifty-one (46%) of the 111
MRSA-positive patients had a known history of
MRSA (risk group 1; Table 3) and 76 (68.5%) were
residents of a nursing home (Table 3). However,
none of these patients had the risk-factor of acute
sialadenitis, and none were admitted directly
from foreign hospitals (Table 3).
Forty-eight patients in the control period had
an HA-MRSA-I, compared with only 38 patients
in the screening period. The most common
HA-MRSA-Is in both periods were surgical site
infections, bloodstream infections, pneumonia
and urinary tract infections, with an increasing
number of surgical site infections observed
during the screening period (Table 4).
In October 2002, there was an increasing num-
ber of HA-MRSA-Is (Fig. 1), which may have been
associated with an increasing number of potential
Table 2. Classiﬁcation of MRSA patients during the con-
trol (September 1999 – March 2001) and screening (May
2001 – November 2002) periods, showing their stratiﬁca-
tion into high-risk and non-high-risk MRSA patients, and
their division into MRSA colonisation and MRSA infection
events
Classiﬁcation
Control period
(19 months)
Number of
patients
Screening period
(19 months)
Number of
patients
High-risk MRSA patientsa
with nosocomial MRSA infection 10 4
with community-acquired MRSA infection 18 11
with MRSA colonisation 23 99
All high-risk MRSA patients 51 114
Non-high-risk MRSA patients
with nosocomial MRSA infection 38 34
with community-acquired MRSA infection 16 11
with MRSA colonisation 14 46
All non-high-risk MRSA patients 68 91
All MRSA patients 119 205
aHigh-risk MRSA patients had risk factors that qualiﬁed them for screening. High-
risk patients were only screened during the screening period and were isolated
upon hospital admission until they were shown to be MRSA-negative.
Table 3. Risk-factors for MRSA carriage by the MRSA
patients detected from screening samples at hospital
admission during the screening period (May 2001 –
November 2002)
Risk factors
Number of MRSA
patients (n = 111)
Risk group 1 51
Readmitted patients with a known history of MRSAa 39
with no other risk-factor 8
with decubital ulcer 8
with invasive devices 1
with decubital ulcer and invasive devices 1
with diabetic gangrene 1
with decubital ulcer and diabetic gangrene 1
residents of nursing homes 1
residents of nursing homes with invasive devices 5
residents of nursing homes with decubital ulcer 2
residents of nursing homes with invasive
devices and decubital ulcer
10
residents of nursing homes with decubital
ulcer and diabetic gangrene
1
MRSA carriers diagnosed by external
microbiological examination
12
with no other risk factor 7
with necessity for dialysis with skin
or soft tissue infection
1
with decubital ulcer and diabetic gangrene 1
residents of nursing homes with invasive devices 1
residents of nursing homes with invasive
devices and decubital ulcer
1
residents of nursing homes with invasive
devices and diabetic gangrene
1
Risk group 2 59
Residents of nursing homes with invasive devices 22
Residents of nursing homes with decubital ulcer 6
Residents of nursing homes with invasive
devices and decubital ulcer
23
Residents of nursing homes with diabetic gangrene 2
Residents of nursing homes with invasive
devices and diabetic gangrene
1
Patients with invasive devices and decubital ulcer 4
Patients with decubital ulcer and diabetic gangrene 1
Risk group 3 1
Patients admitted from a foreign hospital 0
Patients admitted from a hospital where MRSA is endemic 1
aIdentiﬁed at hospital admission because of marking in the computer admission
system
Table 4. Patients with nosocomial MRSA infection (based
on CDC criteria), sub-divided by type of infection during
the control (September 1999 – March 2001) and screening
(May 2001 – November 2002) periods
Type of nosocomial MRSA infection
Control period
(19 months)
Number of
patients (%)a
Screening period
(19 months)
Number of
patients (%)a
All surgical site infections 14 (29.2) 16 (42.1)
Superﬁcial incisional surgical site infection 3 9
Deep incisional surgical site infection 7 4
Organ ⁄ space surgical site infection 4 3
Bloodstream infections 13 (27.1) 7 (18.4)
Urinary tract infection 7 (14.6) 3 (7.9)
Pneumonia 6 (12.5) 3 (7.9)
Device-associated pneumonia 4 3
Tracheobronchitis 4 (8.3) 2 (5.3)
Venous catheter associated skin infection 3 (6.2) 3 (7.9)
Other infections 1 (2.1) 4 (10.5)
All nosocomial MRSA infections 48 38
aPercentage of all nosocomial MRSA infections in the corresponding group.
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MRSA carriers who were not screened because of
non-compliance. Six of the seven HA-MRSA-Is in
this month were surgical site infections (more
than one-third of all surgical site infections
observed during the screening period), which
may account for the overall increase in the
number of surgical site infections compared with
the control period. HA-MRSA-I rates decreased
when infection control compliance improved
(Fig. 1, follow-up period), thereby illustrating that
continuous surveillance and staff education is
essential for realisation of such a large pro-
gramme.
MRSA was the only causative pathogen in
66.7% of HA-MRSA-Is during the control period,
and in 69.8% of HA-MRSA-Is during the screen-
ing period. In both study periods, ST 22 and ST 45
were the predominant epidemic MRSA strains.
There was a relative frequency of HA-MRSA-Is
of 19.6% in high-risk patients and of 55.9% in
non-high-risk patients during the control period
(Table 5). Using these relative frequencies, a total
of 73.2 HA-MRSA-Is were expected during the
screening period (Table 5), but only 38
HA-MRSA-Is were actually observed during that
period, thereby indicating that 35.2 HA-MRSA-Is
were prevented during a period of 19 months.
Dividing the observed number of 38 HA-MRSA-Is
in the screening period by the expected number of
73.2 HA-MRSA-Is yields an SIR value of 0.52
(Table 5), indicating that only 52% of the expec-
ted number of HA-MRSA-Is were actually
observed (i.e., 48% of HA-MRSA-Is were preven-
ted by the screening programme). This reduction
was statistically signiﬁcant (Table 5). When sub-
divided into types of HA-MRSA-I, there were
signiﬁcantly less bloodstream infections and urin-
ary tract infections caused byMRSA (Table 5). The
reduction in cases of hospital-acquired pneumonia
and tracheobronchitis caused by MRSA was not
statistically signiﬁcant.
For validation purposes, 678 items of data for
32 patients were collected independently by a
second investigator and were conﬁrmed in 648
(95.6%) instances.
DISCUSSION
There is an increasing incidence of MRSA in
many countries around the world. Therapeutic
options are often few and can be associated with
more adverse effects than are agents used for
treatment of infections caused by methicillin-
sensitive S. aureus (MSSA) strains. MRSA blood-
stream infections are associated with a higher
mortality than are MSSA bloodstream infections
[21]. There has been an increasing number of
reports of glycopeptide-intermediate S. aureus
strains (GISA), and the ﬁrst vancomycin-resistant
S. aureus has been reported [22]. Reserve antibi-
otics, e.g., linezolid and quinupristin ⁄dalfopristin
are very expensive, and costs for treatment of
HA-MRSA-Is are much higher than for infections
caused by MSSA [23,24]. Therefore, it is important
to implement well-evaluated strategies which
prevent the spread of this multiresistant pathogen.
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Fig. 1. Monthly incidence of patients
with nosocomial MRSA infection
(based on CDC criteria) and all MRSA
patients during the entire study (con-
trol period September 1999 to March
2001; screening period May 2001 to
November 2002) and the follow-up
period.
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The present study indicates that a possible reduc-
tion in HA-MRSA-Is can be achieved with select-
ive screening, even in a situation where MRSA is
endemic in a hospital located in a country with an
increasing prevalence of MRSA.
The increasing prevalence of MRSA in Germany
is one possible explanation for the fact that the
screening programme did not reduce the overall
frequency of all MRSA patients; indeed, this
frequency increased continuously during the
entire study period (Fig. 1). Screening and decol-
onisation measures were not performed as strictly
in most of the hospitals in the region as they were
in the study hospital. Therefore, many patients
can become colonised by MRSA in other hospi-
tals, and then increase the overall frequency of
MRSA patients if they are admitted to the study
hospital. To reduce the overall MRSA frequency,
a very strict ‘search and destroy strategy’, as used
in The Netherlands and Denmark in all hospitals
of a region with an MRSA problem, is needed.
Another possibility is that the active search
strategy during the screening programme resul-
ted in the detection of more MRSA patients at
hospital admission than during the control per-
iod. However, there was a continuous increase in
the frequency of MRSA from the beginning of the
control period, and there was no abrupt rise
following the introduction of the screening pro-
gramme (Fig. 1). It is important to understand
these two effects when interpreting the efﬁciency
of a screening programme. If hospitals introduce
such a programme, they should not be disap-
pointed if there is no decrease in the overall
frequency of isolation of MRSA.
There are three possible ways in which such a
screening programme can make an impact. First,
early identiﬁcation of MRSA carriers and isolation
of these patients reduces transmission to other
patients. Jernigan et al. [25] showed that the
transmission rate was signiﬁcantly higher when
contacts of MRSA patients were not isolated (the
relative risk in the present study was 15.6 in the
absence of contact isolation measures). Second,
nasal carriage of MRSA increases the risk of
endogenous MRSA infection [26]. Therefore, it is
conceivable that early detection and decolonisa-
tion reduces the risk of endogenous hospital-
acquired infection. Third, such a screening
programme increases awareness and compliance
with standard hygiene measures such as hand
disinfection.
Table 5. Comparison of standardised infection ratios for all patients with nosocomial MRSA infection (HA-MRSA-I),
patients with nosocomial MRSA septicaemia and patients with nosocomial MRSA urinary tract infection (MRSA-UTI) in
the control (September 1999 – March 2001) and screening (May 2001 – November 2002) periods
Patient type
Control period Screening period
Number of
patients
Patients with
HA-MRSA-I
Percentage of
HA-MRSA-I
patients (%)
Number of
patients
Expected number
of patients with
HA-MRSA-I
Observed patients
with HA-MRSA-I
Standardised
infection ratioa
High-risk MRSA patients 51 10 19.6 114 22.3 (19.6% of 114) 4
Non-high-risk MRSA-patients 68 38 55.9 91 50.9 (55.9% of 91) 34
All 119 48 – 205 73.2 (22.3 + 50.9) 38 0.52 (38 ⁄ 73.2)
95% CI: 0.37–0.71
Number of
patients
Patients with
MRSA septicaemia
Percentage of
patients with MRSA
septicaemia (%)
Number of
patients
Expected
number of
patients with
MRSA septicaemia
Observed patients
with MRSA
septicaemia
Standardised
infection ratio
High-risk MRSA patients 51 3 5.9 114 6.7 (5.9% of 114) 0
Non-high-risk MRSA-patients 68 10 14.7 91 13.4 (14.7% of 91) 7
All 119 13 – 205 20.1 (6.7 + 13.4) 7 0.35 (7 ⁄ 20.1)
95% CI: 0.14–0.71
Number of
patients
Patients with
MRSA-UTI
Percentage of
patients with
MRSA-UTI (%)
Number of
patients
Expected
number of
patients with
MRSA-UTI
Observed patients
with MRSA-UTI
Standardised
infection ratio
High-risk MRSA patients 51 0 0 114 0 (0% of 114) 1
Non-high-risk MRSA-patients 68 7 10.3 91 9.36 (10.3% of 91) 2
All 119 7 – 205 9.36 3 0.32 (3 ⁄ 9.36)
95% CI: 0.06–0.94
aCalculated by dividing the number of observed patients with HA-MRSA-I in the screening period by the expected number of patients
with HA-MRSA-I calculated from nosocomial infection rates during the control period. A 95% CI not including a value of 1.0 was considered to be statistically signiﬁcant.
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Screening of all patients is more expensive than
selective screening of deﬁned risk groups, and is
more likely to be enforceable in high-risk areas
such as ICUs, or in hospitalswith a small number of
admissions. There seems to be no difference in
sensitivity between selective screening and screen-
ing of all patients in an endemic situation [27],
provided that the screening criteria are well-
deﬁned. Papia et al. [5] performed hospital-wide
screening of patients transferred directly from
another healthcare facility, patients who had been
hospitalised or lived in a nursing home in
the 3 months before admission, and known
MRSA-positive patients, corresponding to 10% of
all admissions. Girou et al. [16] performed selective
screening of 44% of all admissions to a medical
ICU, of whom 8% were found to be MRSA-
positive. In the present study, only 1.5% of all
admissions met the screening criteria, of whom
20.6% were MRSA-positive. For patients in risk
group 3 (i.e., residing in a nursing home, receiving
dialysis with skin or soft tissue infection, an
invasive device, decubital ulcer, aged >65 years
with acute sialadenitis or diabetic gangrene), the
existence of two of these risk factors was required
before screening was performed. This was helpful
in detecting a sufﬁcient number of carriers while
keeping the workload for the screening pro-
gramme relatively low.
It is important to stress that no measure to
prevent MRSA transmission – other than screen-
ing – was changed between the control and the
screening periods; therefore, the reduction in
HA-MRSA-Is can presumably be attributed to
the screening and preventive contact isolation of
potential MRSA carriers, although a possible
limitation of the study is the comparison with a
retrospective control period and retrospective
data collection during that period. Since there is
a large variation in the MRSA epidemiology
between countries and regions, and even be-
tween different departments in the same hospi-
tal, it seemed impractical to ﬁnd a comparable
institution in order to compare prospectively the
inﬂuence of screening on HA-MRSA-Is rates,
since it is probably unethical to compare
HA-MRSA-Is rates with a hospital where no
effort is made to reduce these rates. The general
characteristics of the two study period popula-
tions were comparable, and hence this limitation
should be minimal. Using a cohort study seemed
to be the most suitable design since randomisa-
tion was not possible with hospital-wide
screening.
In conclusion, the present study showed that
selective screening for potential MRSA carriers at
hospital admission, with preventive contact isola-
tion precautions as recommended in guidelines
[1,2], may be able to prevent HA-MRSA-Is,
especially bloodstream infections and urinary
tract infections, even in a situation where MRSA
is endemic in the hospital and there is an overall
increasing incidence of MRSA in patients. The
screening programme was performed with min-
imal effort (it was necessary to screen only 1.5%
of all inpatients) and can therefore be recommen-
ded as an effective hygiene measure in preventing
HA-MRSA-I.
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